Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Richard Pops will deliver a corporate overview and update on Wednesday, Jan. 15, 2025, at 11:15 a.m. PST, followed by a Q&A session. The presentation will be accessible via webcast on the company's website under the Investors tab and will remain archived for 14 days.

Alkermes is a global biopharmaceutical company focused on neuroscience innovation. Their portfolio includes commercial products treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company's pipeline features clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia. Based in Ireland, Alkermes maintains a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.

News Market Reaction – ALKS

+1.01%

1 alert

+1.01% News Effect

On the day this news was published, ALKS gained 1.01%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

DUBLIN, Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43^rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 15, 2025 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302341496.html

SOURCE Alkermes plc

FAQ

When is Alkermes (ALKS) presenting at the 2025 J.P. Morgan Healthcare Conference?

Alkermes will present on Wednesday, January 15, 2025, at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT).

How long will the ALKS J.P. Morgan Conference presentation webcast be available?

The webcast will be archived and available for 14 days following the presentation on Alkermes' website under the Investors tab.

What therapeutic areas does Alkermes (ALKS) currently focus on?

Alkermes focuses on neuroscience, with products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, plus pipeline candidates for neurological disorders including narcolepsy and idiopathic hypersomnia.

Where are Alkermes' (ALKS) main operational facilities located?

Alkermes is headquartered in Ireland, with a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.